WAM
PTGX icon

Weiss Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Weiss Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
14,209
+4,429
+45% +$463K 0.02% 360
2026
Q1 		$1.03M Buy
+9,780
New +$866K 0.02% 328
2025
Q4 		– Sell
-14,310
Closed -$951K – 795
2025
Q3 		$951K Buy
+14,310
New +$813K 0.01% 361
2024
Q4 		– Sell
-62,463
Closed -$2.81M – 824
2024
Q3 		$2.81M Buy
+62,463
New +$2.52M 0.06% 279

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Weiss Asset Management's PTGX Position: Q2 2026 in Review

Weiss Asset Management increased its Protagonist Therapeutics (PTGX) stake by 45% in Q2 2026, buying an estimated $463K and bringing the position to 14,209 shares worth $1.74M. The position accounts for 0.02% of the portfolio, ranked #360.

Weiss Asset Management first reported a position in PTGX in Q3 2024 and has held it in 4 quarters since. The position peaked at $2.81M in Q3 2024. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Weiss Asset Management held 14,209 shares of Protagonist Therapeutics worth $1.74M as of Q2 2026.
  • Weiss Asset Management bought 4,429 Protagonist Therapeutics shares in Q2 2026, an estimated $463K.
  • Protagonist Therapeutics made up 0.02% of Weiss Asset Management's portfolio in Q2 2026, its #360 holding.
  • Weiss Asset Management first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Weiss Asset Management's Protagonist Therapeutics position peaked at $2.81M in Q3 2024.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Weiss Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.